Clinical Trial Update: Treatment of Epidermolysis Bullosa Dystrophica by Polyphenon E (Epigallocatechin 3 Gallate) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of Polyphenon E (epigallocatechin-3-gallate) for epidermolysis bullosa dystrophica has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epidermolysis Bullosa Dystrophica

Drugs mentioned

• Polyphenon E (sinecatechin)

Snippet

Sponsor: Centre Hospitalier Universitaire de Nice | Conditions: Epidermolysis Bullosa Dystrophica | Phase 2 | Status: COMPLETED